FindTrial
Sign In

Genomics and proteomics study on spinal metastases of hepatocellular carcinoma

Genomics and proteomics study on spinal metastases of hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016324
Enrollment
Unknown
Registered
2018-05-25
Start date
2017-12-01
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

spinal metastases of hepatocellular carcinoma

Interventions

Case series :NA

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Signed informed consent; 2. Aged between 18 and 75 years; 3. primary cancer is hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: 1. The objects refused to sign the informed consent; 2. The primary cancer site is central nervous system or spine; 3. More than one primary cancer; 4. The patients refused to be followed up; 5. Mental, intellectual disabilities or other communication disorders.

Design outcomes

Primary

MeasureTime frame
Genomics;Proteomics;—

Countries

China

Contacts

Public ContactJianru Xiao

Department of Orthopaedic Oncology, Changzheng Hospital

jianruxiao83@163.com+86 13701785283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026